Promising Results with Elranatamab + Iberdomide from MagnetisMM-30| Attaya Suvannasankha, MD

Promising Results with Elranatamab + Iberdomide from MagnetisMM-30| Attaya Suvannasankha, MD
PROMISE Study Results: Time to Start Screening for Myeloma? | Irene Ghobrial, MD
The "No More MGUS" Project: Why It's Time to End "Undetermined" in MGUS | Bruno Paiva, PhD
What’s New for Newly Diagnosed Multiple Myeloma | Rahul Banerjee, MD, FACP
ReKInDLE study: Iberdomide Quadruplet Shows Promising Results | Benjamin Diamond, MD
IMMUNOPLANT-Will Linvoseltamab Consolidation Replace ASCT? | Dickran Kazandjian, MD
Treating High Risk Smoldering Multiple Myeloma- Aquila Updates | Natalie Callander, MD
Your Voice Matters: The Power of Patient-Reported Outcomes in Myeloma | Fabio Efficace, PhD
Updates -Smoldering Multiple Myeloma from ASH 2025 | Rahul Banerjee, MD, FACP
Anito-cel (a BCMA CAR-T) : Shows No Cases of Delayed Neurotoxicity | Natalie Callander, MD
S100A8 -a new target to prevent T cell exhaustion BsAbs in myeloma | Adolfo Aleman, PhD
Fewer Bone Marrow Biopsies? Using Blood & Whole Genome Sequencing | Chrissy Baker, MSc
Making CAR-T Cells inside the body? inMMyCAR Trial Insights | Natalie Callander, MD
Does MGIP represent the earliest stage of myeloma? | Sungjae Kim, PhD
Etentamig in patients with relapsed refractory amyloidosis | Rajshekhar Chakraborty, MD
Update on Arlo-Cel, a GPRC5D CAR-T, in RRMM | Ciara Freeman, MD, PhD
AI Using Multimodal Datasets to Predict Response to CAR-T Treatment | Ciara Freeman, MD, PhD
Prophylactic Tocilizumab to Prevent CRS During Bispecific Step-up Dosing | Astrid Torpe, MD